Search
Search
Search results 21
MHLW Approves AmoyDx® Pan Lung Cancer PCR Panel as Companion Diagnostic for Rozlytrek® (Entrectinib) in Japan
TOKYO and XIAMEN, August 9, 2022 -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”) had been approved by t
News & Events
Filing Notice for a Manufacturing and Marketing Application for AmoyDx® Pan Lung Cancer PCR Panel as a Companion Diagnostic for a Drug Targeting RET fusion-Positive Non-Small Cell Lung Cancer
TOKYO and XIAMEN, April 20, 2022 -- Riken Genesis Co., Ltd., (“Rigen Genesis”), Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that in April 2022, AmoyDx® Pan Lung Cancer PCR Panel (the “
News & Events
Notice Concerning Application for Partial Revision of Manufacturing and Marketing Approval of Companion Diagnostic Reagent for the AmoyDx® Pan Lung Cancer PCR Panel
TOKYO and XIAMEN, February 24, 2022 -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that an application for partial revision of manufacturing and marketing approval for Am
News & Events
AmoyDx Announces Its PLC Panel Adopted as Companion Diagnostic for Brigatinib in Japan
Xiamen, China, January 29, 2022 - Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685), an innovative commercial-stage in vitro diagnostic (IVD) company today announced that the AmoyDx Pan Lung Cancer PCR Panel (the “PLC Panel”) has been adopted by Takeda Ph
News & Events
AmoyDx and PREMIA Announce the Commercial Launch of the AmoyDx® Pan Lung Cancer PCR Panel in Japan
Xiamen and Hong Kong, January 14, 2022 -- Amoy Diagnostics Co., Ltd., (“AmoyDx”) and PREMIA Holdings (HK) Limited (“PREMIA”) today announced the commercial launch of the AmoyDx® Pan Lung Cancer PCR Panel (the “PLC Panel”) in Japan as a reimbursed companio
News & Events
AmoyDx Collaborates with Amgen to Develop Companion Diagnostics for Japan Market
Xiamen, China, Aug 19, 2021 - Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685), an innovative commercial-stage in vitro diagnostic (IVD) company, and Amgen Inc. (NASDAQ: AMGN), announced today that the companies have entered into a strategic collaboratio
News & Events
AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval as Companion Diagnostic for TEPMETKO® (tepotinib)
TOKYO and XIAMEN, August 17, 2021 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd. (“AmoyDx”), and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the Ministry of Health, Labour and Welfare (MHLW) has approved the
News & Events
AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval as Companion Diagnostic for 9 Targeted Therapies for Use in Patients with Advanced Non-Small Cell Lung Cancer
TOKYO and XIAMEN, June 30, 2021 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx® PLC Panel”), an i
News & Events
AmoyDx Signs Agreement with Haihe Biopharma to Co-develop Companion Diagnostics for the United States Market
Xiamen, China, March 12, 2021 – Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) and Haihe Biopharma announced that they signed an agreement to use the MET mutation detection kit of AmoyDx as Companion Diagnostic (CDx) assay supporting the registration o
News & Events
AmoyDx Collaborates with Haihe Pharmaceutical to Codevelop Companion Diagnostics for Japan Market
Xiamen, China, August 27, 2020– Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with Haihe Pharmaceutical to develop a Companion Diagnostic (CDx) test supporting the novel MET inhibitor Glumetinib (SCC244). The CDx
News & Events
AmoyDx Collaborates with Merck KGaA, Darmstadt, Germany to Develop Companion Diagnostics for Japan Market
Xiamen, China, 9:00am, August 10, 2020– Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with Merck KGaA, Darmstadt, Germany, to develop a Companion Diagnostic (CDx) test supporting the novel MET inhibitor tepotinib.
News & Events
MHLW Approves AmoyDx® Pan Lung Cancer PCR Panel as Companion Diagnostic for Rozlytrek® (Entrectinib) in Japan
News & Events
Pan Lung Cancer PCR Panel
PRODUCTS
AmoyDx® Pan Lung Cancer PCR Panel-P1.4-8T-RUO (LC480)
DOWNLOAD
AmoyDx® Pan Lung Cancer PCR Panel-P2.4-8T-RUO (QS5)
DOWNLOAD
AmoyDx® Pan Lung Cancer PCR Panel-P1.5-8T-CE (LC480 z480)
DOWNLOAD
AmoyDx® Pan Lung Cancer PCR Panel-P2.2-8T-CE(QS5)
DOWNLOAD
AmoyDx® Pan Lung Cancer Detection Reagent (V2) - (for Color Compensation)-B1.0-J-12T
DOWNLOAD
AmoyDx® Pan Lung Cancer Detection Reagent (V2)
DOWNLOAD
AmoyDx®Pan Lung Cancer PCR Panel
DOWNLOAD
AmoyDx® Pan Lung Cancer PCR Panel - Innovative Multi-gene Testing for NSCLC by qPCR
Speaker: Paul Huang (AmoyDx), Matthias Mueser (AmoyDx), Daniel Giner (AmoyDx), Agata Page (Unilabs)
Videos
no more...
MHLW Approves AmoyDx® Pan Lung Cancer PCR Panel as Companion Diagnostic for Rozlytrek® (Entrectinib) in Japan
TOKYO and XIAMEN, August 9, 2022 -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”) had been approved by t
News & Events
Filing Notice for a Manufacturing and Marketing Application for AmoyDx® Pan Lung Cancer PCR Panel as a Companion Diagnostic for a Drug Targeting RET fusion-Positive Non-Small Cell Lung Cancer
TOKYO and XIAMEN, April 20, 2022 -- Riken Genesis Co., Ltd., (“Rigen Genesis”), Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that in April 2022, AmoyDx® Pan Lung Cancer PCR Panel (the “
News & Events
Notice Concerning Application for Partial Revision of Manufacturing and Marketing Approval of Companion Diagnostic Reagent for the AmoyDx® Pan Lung Cancer PCR Panel
TOKYO and XIAMEN, February 24, 2022 -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that an application for partial revision of manufacturing and marketing approval for Am
News & Events
AmoyDx Announces Its PLC Panel Adopted as Companion Diagnostic for Brigatinib in Japan
Xiamen, China, January 29, 2022 - Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685), an innovative commercial-stage in vitro diagnostic (IVD) company today announced that the AmoyDx Pan Lung Cancer PCR Panel (the “PLC Panel”) has been adopted by Takeda Ph
News & Events
AmoyDx and PREMIA Announce the Commercial Launch of the AmoyDx® Pan Lung Cancer PCR Panel in Japan
Xiamen and Hong Kong, January 14, 2022 -- Amoy Diagnostics Co., Ltd., (“AmoyDx”) and PREMIA Holdings (HK) Limited (“PREMIA”) today announced the commercial launch of the AmoyDx® Pan Lung Cancer PCR Panel (the “PLC Panel”) in Japan as a reimbursed companio
News & Events
AmoyDx Collaborates with Amgen to Develop Companion Diagnostics for Japan Market
Xiamen, China, Aug 19, 2021 - Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685), an innovative commercial-stage in vitro diagnostic (IVD) company, and Amgen Inc. (NASDAQ: AMGN), announced today that the companies have entered into a strategic collaboratio
News & Events
AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval as Companion Diagnostic for TEPMETKO® (tepotinib)
TOKYO and XIAMEN, August 17, 2021 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd. (“AmoyDx”), and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the Ministry of Health, Labour and Welfare (MHLW) has approved the
News & Events
AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval as Companion Diagnostic for 9 Targeted Therapies for Use in Patients with Advanced Non-Small Cell Lung Cancer
TOKYO and XIAMEN, June 30, 2021 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx® PLC Panel”), an i
News & Events
AmoyDx Signs Agreement with Haihe Biopharma to Co-develop Companion Diagnostics for the United States Market
Xiamen, China, March 12, 2021 – Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) and Haihe Biopharma announced that they signed an agreement to use the MET mutation detection kit of AmoyDx as Companion Diagnostic (CDx) assay supporting the registration o
News & Events
AmoyDx Collaborates with Haihe Pharmaceutical to Codevelop Companion Diagnostics for Japan Market
Xiamen, China, August 27, 2020– Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with Haihe Pharmaceutical to develop a Companion Diagnostic (CDx) test supporting the novel MET inhibitor Glumetinib (SCC244). The CDx
News & Events
AmoyDx Collaborates with Merck KGaA, Darmstadt, Germany to Develop Companion Diagnostics for Japan Market
Xiamen, China, 9:00am, August 10, 2020– Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with Merck KGaA, Darmstadt, Germany, to develop a Companion Diagnostic (CDx) test supporting the novel MET inhibitor tepotinib.
News & Events
MHLW Approves AmoyDx® Pan Lung Cancer PCR Panel as Companion Diagnostic for Rozlytrek® (Entrectinib) in Japan
News & Events
no more...
Inquiry
* Required information
Manage your account info
Change your password